252 related articles for article (PubMed ID: 35193828)
21. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
22. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
[TBL] [Abstract][Full Text] [Related]
23. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.
Xia Y; Wang D; Piao Y; Chen M; Wang D; Jiang Z; Liu B
Front Immunol; 2022; 13():1025532. PubMed ID: 36457998
[TBL] [Abstract][Full Text] [Related]
24. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
[TBL] [Abstract][Full Text] [Related]
25. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner J; Wickman E; DeRenzo C; Gottschalk S
Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
[TBL] [Abstract][Full Text] [Related]
26. CAR T-cells to treat brain tumors.
Guzman G; Pellot K; Reed MR; Rodriguez A
Brain Res Bull; 2023 May; 196():76-98. PubMed ID: 36841424
[TBL] [Abstract][Full Text] [Related]
27. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
28. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
29. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
30. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
Lin YJ; Mashouf LA; Lim M
Front Immunol; 2022; 13():817296. PubMed ID: 35265074
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
[TBL] [Abstract][Full Text] [Related]
32. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract][Full Text] [Related]
33. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
34. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
35. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
36. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
37. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
38. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
39. Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy.
Chen Z; Pan H; Luo Y; Yin T; Zhang B; Liao J; Wang M; Tang X; Huang G; Deng G; Zheng M; Cai L
Small; 2021 Apr; 17(14):e2007494. PubMed ID: 33711191
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]